Satralizumab is a humanized monoclonal antibody that inhibits interleukin-6 (IL-6) receptor. Satralizumab has been developed for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.